AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7697843
Drug: 90-micrograms/kg bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 4 hours
Trial: 7697843
Drug: 90-micrograms/kg bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 12 hours
Trial: 23315286
Drug: 0.1 l/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 l/min 100% oxygen
Trial: 23315286
Drug: 0.1 l/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 l/min air (21% oxygen)
Trial: 23315286
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (tubing disconnected from flow-meter)
Trial: 26688733
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily
Trial: 29282768
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patches
Trial: 29554173
Drug: Vaginal 10-μg
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal 10-μg estradiol tablet
Trial: 19912212
Drug: Degarelix subcutaneous
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix subcutaneous 240 mg for 1 month followed by monthly maintenance doses of 80 mg or 160 mg
Trial: 19962227
Drug: Leuprolide 7.5
RxNorm normalized name: leuprolide 7.5 mg/month intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide 7.5 mg/month
Trial: 1621239
Drug: MF 701,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF 701, 300 mg IM b.i.d. (second phase)
Trial: 18534218
Drug: Low-dose indomethacin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose indomethacin (0.1 mg/kg/d)
Trial: 18534218
Drug: Higher-dose indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose indomethacin (0.2 or 0.5 mg/kg/d)
Trial: 15755044
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (leuprolide acetate)
Trial: 14557467
Drug: oral glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral glucose, iv octreotide
Trial: 14557467
Drug: oral glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral glucose, iv saline
Trial: 11050700
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release chitosan formulation of pentoxifylline
Trial: 6139745
Drug: Steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids and sulfasalazine (group A)
Trial: 6139745
Drug: Elementary diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elementary diet with steroids and sulfasalazine (group C)
Trial: 22902096
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg daily)
Trial: 10710049
Drug: Oral (p.o.)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (p.o.) pantoprazole (40 mg and 20 mg)
Trial: 8452191
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg
Trial: 1485530
Drug: Raclopride 2‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raclopride 2‐8 mg twice daily
Trial: 1485530
Drug: Haloperidol 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5‐20 mg twice daily
Trial: 28507219
Drug: Subcutaneous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous golimumab (30 mg/m2 of body surface area; maximum: 50 mg/dose) every 4 weeks with weekly methotrexate
Trial: 15978098
Drug: Epsilon aminocaproic
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon aminocaproic acid (EACA) (10 g over 30 min followed by 5 g over 3 h)
Trial: 12679467
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human FSH (r‐hFSH) at doses of 0, 37.5, 75, or 150 IU
Trial: 12679467
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human FSH (r‐hFSH) at doses of 37.5 IU and 75 IU
Trial: 31523919
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment (power 12 W, time on 3 ms, PPI 5), two sessions four weeks apart
Trial: 31523919
Drug: Topical keratolytic
RxNorm normalized name: KERATOLYTICS/CAUSTICS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical keratolytic (10% urea)
Trial: 20120420
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment
Trial: 23859414
Drug: Sauna treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sauna treatment (30 minutes, 3 days per week for 6 weeks)
Trial: 9679792
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/d)
Trial: 12115946
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (CP; n = 12)
Trial: 25939797
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 4 weeks
Trial: 2299367
Drug: Empiric antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antimicrobial therapy (ET)
Trial: 2299367
Drug: Complication rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complication rate comparison between patients receiving only empiric antibiotics and all patients having an OLB
Trial: 24046309
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oseltamivir twice daily for 5 days
Trial: 24046309
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oseltamivir (subanalysis for influenza B)
Trial: 24046309
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oseltamivir (subanalysis for influenza B)
Trial: 11700183
Drug: Vaccine (180,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (180, 360, and 540 microg doses)
Trial: 8273795
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g amoxicillin tid intravenously (n = 15)
Trial: 15946144
Drug: rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10)
Trial: 10078677
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg acetaminophen orally (placebo)
Trial: 8652038
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium (10 mg for < 55 kg; 20 mg for > 55 kg)
Trial: 8652038
Drug: Nordiazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiazepam (1 gtt/kg; 5 mg = 24 gtt)
Trial: 6444862
Drug: Actinac (lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actinac (lotion with chloramphenicol)
Trial: 6444862
Drug: Formulation without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation without chloramphenicol
Trial: 26083828
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (recombinant hepatitis B)
Trial: 20002013
Drug: Rapid enteral
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid enteral feeding advancement at 30 mL/kg/day
Trial: 16183794
Drug: Oral magnesium-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral magnesium-containing drugs
Trial: 16183794
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (control group without magnesium drugs)
Trial: 14581795
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition (n = 18)
Trial: 25972515
Drug: Daikenchuto (15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (15.0 g/day, t.i.d)
Trial: 16124431
Drug: Ivermectin, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin, single dose of 50, 100, 150, or 200 microg/kg bodyweight
Trial: 16124431
Drug: Albendazole, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole, 400 mg twice a day for 14 days
Trial: 10480630
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg/day for 4 weeks)
Trial: 8916820
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg in 10 ml 0.9% saline
Trial: 2064488
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous (IV) injections of morphine sulfate 4 mg every 30 to 60 minutes (phase 1)
Trial: 2064488
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with morphine sulfate 2 mg bolus then 1.0 mg with a 6-minute lockout (phase 1)
Trial: 6698443
Drug: High sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sugar diet (112 g refined sucrose)
Trial: 31256656
Drug: Fructosamine >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructosamine > 293 µmol/l
Trial: 9220304
Drug: Standard Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive Therapy (SCT)
Trial: 9220304
Drug: Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused Cognitive Therapy (FCT)
Trial: 8192475
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of vancomycin per kg of body weight before anesthesia
Trial: 8192475
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of vancomycin per kg of body weight before anesthesia and a second 7.5‐mg/kg dose at the time of initiation of cardiopulmonary bypass
Trial: 3791247
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg AZQ/m2/day, i.v., for 3 consecutive days, every 4 weeks
Trial: 3791247
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BCNU/m2, i.v., every 8 weeks
Trial: 28831250
Drug: Regular medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medical treatment (Control)
Trial: 20542963
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) prednisone
Trial: 8456144
Drug: Flexibility training
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexibility training (n = 9): performed postural control exercises weekly
Trial: 31167863
Drug: ICAN QUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICAN QUIT in Pregnancy intervention (three 1-hour webinar sessions, educational resource package, and free oral NRT)
Trial: 27310332
Drug: CTP-499 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTP-499 (600 mg orally once daily for 2 weeks, then twice daily for 2 additional weeks)
Trial: 20923244
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg and metformin 500 mg co-administration
Trial: 20923244
Drug: Sitagliptin/metformin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/metformin 50 mg/1000 mg FDC tablet
Trial: 20923244
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg and metformin 1000 mg co-administration
Trial: 15957835
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (SFI) - 40 ml intravenous injection, once a day for 7 days
Trial: 7759696
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (6 g of n‐3 fatty acids)
Trial: 18492834
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil capsules (control)
Trial: 12506181
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules
Trial: 365665
Drug: Antacid (aluminum‐magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (aluminum‐magnesium hydroxide tablets, 800 mg seven times per day)
Trial: 365665
Drug: Antacid-sulpiride combination
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid-sulpiride combination
Trial: 27810902
Drug: TT4‐L (light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT4‐L (light arm)
Trial: 23703722
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (up to 1000 mg/d)
Trial: 11423928
Drug: Heat-treated yoghurt
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-treated yoghurt (<15 bacteria/ml)
Trial: 9425382
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily amikacin (7.5 mg/kg, n = 27)
Trial: 9425382
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily amikacin (15 mg/kg, n = 27)
Trial: 2893638
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, twice daily for 7 days)
Trial: 2910421
Drug: Intensification period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS using methotrexate, hydrocortisone, and cytosine arabinoside.
Trial: 2910421
Drug: Intensification period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS.
Trial: 21670770
Drug: APC combined
RxNorm normalized name: APC-356433
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APC combined with photodynamic therapy (PDT)
Trial: 11026657
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/wk for 3 months
Trial: 8112439
Drug: Oral terfenadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terfenadine (180 mg q.d., for three days)
Trial: 26017871
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg once a day for 30 days
Trial: 14665499
Drug: Highly efficacious
RxNorm normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly efficacious treatment (n = 257)
Trial: 14665499
Drug: Moderately efficacious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately efficacious treatment (n = 965)
Trial: 14665499
Drug: Mildly efficacious
RxNorm normalized name: SIMPLYTHICK GEL ORAL MILDLY THICK 6GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly efficacious treatment (n = 891)
Trial: 10365809
Drug: Standard-dose ursodeoxycholic
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ursodeoxycholic acid (13-15 mg x kg(‐1) x day(‐1))
Trial: 10365809
Drug: Low-dose ursodeoxycholic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ursodeoxycholic acid (5-7 mg x kg(‐1) x day(‐1))
Trial: 7049706
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 mg daily)
Trial: 22324772
Drug: LipiFlow® Thermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow® Thermal Pulsation System treatment
Trial: 21035609
Drug: 5-week couple
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-week couple therapy intervention (n=18)
Trial: 18727648
Drug: Greater number
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater number of previous preventive treatments
Trial: 16104447
Drug: Chest physical
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest physical therapy (CPT) after thoracotomy
Trial: 9689556
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (150 IU/kg per dose, increasing to 300 IU/kg per dose, every 3 weeks for 6 months)
Trial: 786820
Drug: Sulpiride (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (150 mg daily for the first week, increased to 225 mg in the second week)
Trial: 786820
Drug: Chlordiazepoxide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (30 mg daily for the first week, increased to 45 mg in the second week)
Trial: 7900628
Drug: Enalapril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (angiotensin-converting enzyme inhibitor)
Trial: 19719452
Drug: Single vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccination with modified-live respiratory virus vaccine
Trial: 19719452
Drug: Revaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaccination with modified-live respiratory virus vaccine
Trial: 19719452
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vaccine during finishing phase)
Trial: 16698351
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no analgesics)
Trial: 15604849
Drug: Nontoxic systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontoxic systemic drugs
Trial: 11309833
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange treatment administered every other day for 2 weeks
Trial: 11309833
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to active treatment after failing sham treatment
Trial: 11309833
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to sham treatment after failing active treatment
Trial: 9407564
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at concentrations of 1, 5, 10, and 20 parts per million (ppm)
Trial: 7712700
Drug: Standard 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 75 g oral glucose tolerance test (OGTT)
Trial: 25581661
Drug: Drink-EtOH adjustments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink-EtOH adjustments using transdermal alcohol sensor (TAS) readings and self-reported diaries.
Trial: 21325151
Drug: Dexmedetomidine (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (cumulative dose, 0.4 μg/kg)
Trial: 15910204
Drug: Extended-release mixed
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release mixed amphetamine salts (MAS-XR) 10-30 mg doses
Trial: 12790363
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) 1000 mg injection
Trial: 7773118
Drug: Teachers' administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teachers' administration of questionnaires
Trial: 7773118
Drug: Researchers' administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Researchers' administration of questionnaires
Trial: 387057
Drug: MK-196 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-196 (10 mg daily)
Trial: 387057
Drug: MK-196 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-196 (15 mg daily)
Trial: 20705718
Drug: Low-dose hCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hCG
Trial: 15257812
Drug: Triptorelin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 0.5 mg (group 3)
Trial: 15257812
Drug: Triptorelin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 0.1 mg three times (group 4)
Trial: 15257812
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (group 5)